KOSDAQBiotech & Pharma065660

Anterogen

₩13,100▲ 4.63%2026-11-18 close
Market Cap
₩131.1B
Turnover
₩300M
Volume
20K
Shares out.
10M
PER
—
PBR
1.6×
EPS
-₩80
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Japan approval brings first exports; profit turn so far one quarter

Allostem's Japanese listing has moved into export, but operating losses ran for four straight years through 2025 and the third-quarter 2026 operating profit is so far the only profitable quarter in the disclosed series.

  1. 1

    Revenue in 2025 was KRW 7.54 billion, up 8.7% year on year, rising for two consecutive years from 2024.

  2. 2

    Third-quarter 2026 revenue reached KRW 2.97 billion, up 45.3% year on year, and operating profit of KRW 374 million marked a swing to profit.

  3. 3

    Allostem was listed as a designated regenerative medical product in Japan through a Ministry of Health, Labour and Welfare notice in April 2026, and the company manufactures finished product for its partner Ishin Pharmaceutical.

  4. 4

    Most revenue still comes from Lemodulin, an in-licensed product, while the company's own products, including Cupistem and Quinsell, have struggled commercially.

  5. 5

    Total liabilities at the end of 2025 were KRW 813 million and the debt ratio was 0.9%, so borrowing burden is small, though operating cash outflows continue.

02

Business structure

Anterogen develops and sells stem cell-based cell therapies and rare disease drugs. Its revenue structure leans heavily on products it in-licenses and sells directly. Media reports said Lemodulin merchandise sales made up 92.9% of revenue in the first half of 2025.

A data aggregator put the mix in the second quarter of 2026 at 97% merchandise sales and 3% from Cupistem and other stem cell culture products. Lemodulin, a pulmonary arterial hypertension treatment, continues to be supplied to general hospitals in Korea. Its own products have struggled to gain a foothold.

Cupistem's marketing approval was voluntarily withdrawn, and the cell therapy Quinsell had its approval deleted in June 2026 after its validity period expired. In September 2025, Taivaso failed to secure final reimbursement under Korea's national health insurance.

The most important product is Allostem for dystrophic epidermolysis bullosa, which Anterogen licensed to Japan's Ishin Pharmaceutical in 2015. Ishin ran the clinical development and obtained approval.

The pipeline includes a US Phase 2 trial in diabetic foot ulcers, a Phase 1 exploratory study in knee osteoarthritis, and the shingles candidate ANT-501. Customers are Korean hospitals and the Japanese partner, and competition comes from domestic and overseas cell therapy developers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2B-₩400M−19.9%
2025Q4₩2B-₩500M−23.7%
2026Q1₩2.1B-₩1.1B−51.8%
2026Q2₩2.2B-₩500M−21.7%
2026Q3₩3B₩400M12.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩6.6B-₩4.6B-₩6.8B−70.5%−6.4%16.2%
2023₩6.5B-₩5.1B-₩2.8B−78.1%−2.2%15.4%
2024₩6.9B-₩3.7B-₩2.3B−54.1%−2.1%5.3%
2025₩7.5B-₩2.4B-₩1.4B−32.3%−1.6%0.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue fell from KRW 6.59 billion in 2022 to KRW 6.5 billion in 2023, a 1.4% decline, then rose to KRW 6.93 billion in 2024, up 6.7%, and to KRW 7.54 billion in 2025, up 8.7%. Revenue has grown for two consecutive years from 2024 through 2025.

Among the years from 2022 to 2025, 2025 was the largest and 2023 the smallest. Operating losses were KRW 4.65 billion in 2022, KRW 5.07 billion in 2023, KRW 3.75 billion in 2024, and KRW 2.43 billion in 2025, so the company posted losses in four consecutive years, with the loss narrowing in 2024 and 2025.

The operating margin moved from -70.5% in 2022 and -78.1% in 2023 to -54.1% in 2024 and -32.3% in 2025. The loss attributable to controlling shareholders narrowed from KRW 6.84 billion in 2022 to KRW 1.37 billion in 2025, and net loss figures are identical because there are no non-controlling interests.

Past press coverage pointed to research spending and selling, general and administrative costs that are heavy relative to sales as a structural cause of losses.

Quarterly revenue bottomed at KRW 2.04 billion in the third quarter of 2025 and KRW 2 billion in the fourth quarter, down 2.0% on the prior quarter, before rising to KRW 2.12 billion, KRW 2.2 billion, and KRW 2.97 billion across the first three quarters of 2026, three consecutive quarterly increases.

The first quarter of 2026 had the largest operating loss in the window at KRW 1.1 billion, followed by a KRW 478 million loss in the second quarter and a KRW 374 million operating profit in the third quarter, which marked a swing to profit.

Profit attributable to controlling shareholders also swung to a KRW 745 million profit in the third quarter of 2026, yet the sum of net losses for the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, is KRW 793 million.

Operating cash flow was -KRW 1.02 billion in 2025, a smaller outflow than -KRW 1.99 billion in 2023. Whether the third-quarter profit persists and how much of the sales growth comes from Japan cannot yet be separated from the disclosed figures.

05

Industry analysis

Rare disease drugs serve limited patient populations, so the market is small, and Anterogen's core revenue also relies on rare medicines. In regenerative medicine, Japan has operated a conditional and expedited review system, under which Allostem went through its approval process.

Actual pricing and insurance listing terms after approval will determine the revenue scale, however. In the United States, the FDA's RMAT designation signals faster development but still needs support from Phase 2 results.

Domestic cell therapy markets have been described as difficult for products to gain a foothold even after approval, and Anterogen's Quinsell and Cupistem are cited as examples.

The industry is watching a shift toward off-the-shelf stem cell products with standardized manufacturing, and Anterogen is promoting its three-dimensional culture and cryopreservation platform.

Competition overlaps with domestic and overseas developers that hold cell therapy pipelines, and in Japan the sales capability of partner Ishin Pharmaceutical is the key variable.

Demand indicators are limited given the rare disease profile, so revenue growth depends on approvals and sales performance of individual products.

06

Outlook

In Japan, a July 2026 notice covered the post-approval progress of Allostem and insurance listing for the regenerative medical product Allostem Sheet, and a notice on September 30, 2026 announced collection of export payments. The company has been described as earning a royalty on sales plus a margin on product supply.

The Japanese patient population is estimated at roughly 1,000, and industry commentary in March 2026 floated export potential of about KRW 200 billion a year once full supply begins, though this is an industry estimate rather than a company disclosure.

In the United States, a September 11, 2026 notice covered a change to the US DEB clinical protocol for Allostem Sheet, and the diabetic foot ulcer program is in a US Phase 2 trial.

The Phase 1 exploratory study of the osteoarthritis candidate ANT-301 showed pain and function improvement in six patients, which the company said needs verification at an IR event on November 10, 2026. The shingles candidate ANT-501 confirmed safety in a 4-week repeat-dose non-clinical toxicity study.

In Korea, the suspension of the relevant clinical trial operations runs from November 9 to December 8, 2026.

The next checkpoints are the price and insurance terms in Japan, the pace of initial prescriptions, the timing of the US trial after the protocol change, and export revenue as reflected in the 2026 annual report.

07

Valuation

PER
—
PBR
1.6×
ROE
-0.9%
EPS
-₩80
BPS
₩8,359
Dividend per share
₩0

The price-to-book ratio sits above 1x, and market capitalization is above total equity. Total equity at the end of 2025 of KRW 87.4 billion is entirely attributable to controlling shareholders, and total liabilities of KRW 813 million mean limited financial burden.

Because the sum of net losses over the last four quarters is KRW 793 million, the price-to-earnings ratio is not calculated. Since the third-quarter profit is so far only one quarter, earnings-based multiple comparisons are limited. The dividend yield is effectively zero, so cash returns through dividends are minimal.

The stock trades at a premium to net assets, which makes the durability of the earnings recovery the key variable for reading the multiples. The operating margin improved from -70.5% in 2022 to -32.3% in 2025, and whether that trend continues is the item to track.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Japan approval and first exports

Allostem was listed as a designated regenerative medical product in Japan through an April 2026 notice, and Anterogen manufactures finished product for partner Ishin Pharmaceutical. The company posted a July 2026 insurance listing notice and a September 2026 export payment notice.

With an estimated Japanese patient population of about 1,000, sales scale could vary considerably with pricing and prescription pace.

Sales growth and a third-quarter swing to profit

Revenue has increased for three consecutive quarters since the fourth-quarter 2025 low. Annual revenue also grew for two years in a row through 2025, and the operating loss narrowed from KRW 4.65 billion in 2022 to KRW 2.43 billion in 2025.

US trials and platform technology

The diabetic foot ulcer therapy is in a US Phase 2 trial and holds FDA RMAT designation. A September 2026 notice described a change to the US DEB clinical protocol for Allostem.

At a November 2026 IR event the company highlighted its three-dimensional culture and cryopreservation platform, and said the shingles candidate ANT-501 confirmed safety in repeat-dose non-clinical testing.

09

Bear factors

Commercial track record of in-house products

Because in-house products have been slow to gain a market foothold, commentary holds that follow-on pipeline results will determine growth.

Revenue concentrated in in-licensed products

In the first half of 2025, Lemodulin merchandise sales made up 92.9% of revenue. Because Lemodulin is a rare disease drug, its market is considered limited. A data aggregator put merchandise sales at 97% in the second quarter of 2026, so reducing dependence on in-licensed products remains a task.

Persistent operating losses and trial operations

The company has posted operating losses for four consecutive years through 2025, and operating cash flow was -KRW 1.02 billion in 2025. The first quarter of 2026 had the largest operating loss in the window at KRW 1.1 billion.

On November 9, 2026, the Ministry of Food and Drug Safety suspended the relevant clinical trial operations through December 8, 2026, citing unreported changes to a trial plan among other violations.

10

Risk factors

Regulation and trial operations

A Ministry of Food and Drug Safety suspension followed late reporting of a clinical trial plan change and quality control violations. The suspension runs through December 8, 2026. If trial timelines shift, development schedules could slip alongside the US DEB protocol change.

Dependence on Japanese sales and pricing

Allostem's sales scale could vary widely with the actual price and insurance listing terms. The speed of early prescription uptake in Japan is also cited as a variable for earnings visibility. Because sales depend on partner Ishin Pharmaceutical, results could differ depending on its selling capability.

Uncertainty in clinical results

The Phase 1 exploratory study of ANT-301 reported pain and function improvement in six patients, but this needs verification. As the Taivaso reimbursement failure showed, clinical results can still be constrained at the commercial stage. Until US Phase 2 data for the diabetic foot ulcer program are available, a US revenue base is hard to assess.

11

What to watch next

  1. December 8, 2026

    This is the end of the suspension of clinical trial operations by the Ministry of Food and Drug Safety. Whether trials resume and how the reporting process for trial plan changes is handled are the points to confirm.

  2. By March 31, 2027

    This is the filing deadline for the 2026 annual report. The annual revenue and operating results, fourth-quarter figures, and how much Japanese export revenue is reflected in the annual numbers are the items to check.

  3. Around May 15, 2027

    This is the filing deadline for the first-quarter 2027 report. Whether the third-quarter 2026 profit swing continues into consecutive quarters and whether the share of revenue from products other than Lemodulin changes are the points to confirm.

  4. Timing not set (to be confirmed upon disclosure)

    Data readouts from the US Phase 2 trial in diabetic foot ulcers and the start schedule after the change to the US DEB protocol for Allostem. These disclosures will indicate the timing of US entry.

12

Overall view

Anterogen's disclosed revenue rose to KRW 7.54 billion in 2025, up for two consecutive years, while operating and controlling-shareholder losses narrowed through a four-year run of losses from 2022 to 2025.

The third quarter of 2026 showed a quarterly swing to profit, with revenue of KRW 2.97 billion and operating profit of KRW 374 million. Japanese approval and the start of exports for Allostem could change the business structure, but revenue still depends on in-licensed products such as Lemodulin.

Its in-house products have struggled commercially, with one marketing approval withdrawn and another deleted, and a clinical trial suspension was imposed in November 2026.

Strengths include Japanese sales expansion, US trial progress, and a balance sheet with almost no borrowings, while weaknesses include continued annual losses, reliance on in-licensed products, and clinical and regulatory risk.

The next checkpoints are the end of the suspension on December 8, 2026, the reflection of export revenue in the 2026 annual report, and whether the profit persists in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. thevc.kr
  3. medisobizanews.com
  4. comp.wisereport.co.kr
  5. medicopharma.co.kr
  6. butler.works
  7. comp.fnguide.com
  8. finance.eduinfom.com
  9. dailyinvest.kr
  10. businesspost.co.kr
  11. news1.kr
  12. m.news.nate.com
  13. ilyoweekly.co.kr
  14. biotimes.co.kr
  15. news.nate.com
  16. digitaltoday.co.kr
  17. stockinfo7.com
  18. anterogen.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis